<DOC>
	<DOCNO>NCT00421954</DOCNO>
	<brief_summary>This open-label study assess medication Geodon速 ( Ziprasidone ) pediatric patient , age 13-17 , diagnose psychotic disorder . Eligible adolescent receive Geodon速 7 week stay NYSPI Children 's Day Unit ( CDU ) day . If clinically appropriate , may also stay New York State Psychiatric Institute ( NYSPI ) Schizophrenia Research Unit ( SRU ) inpatient facility .</brief_summary>
	<brief_title>Open-label Ziprasidone Study Psychosis Treatment Adolescents</brief_title>
	<detailed_description>This study open-label assessment feasibility treat adolescent psychotic disorder ( schizophreniform disorder , schizoaffective disorder , psychosis otherwise specify [ NOS ] , major depressive disorder psychotic feature , bipolar disorder psychotic feature ) inpatient day hospital set ziprasidone ( Geodon ) . Ziprasidone second-generation antipsychotic ( SGA ) FDA-approved treatment schizophrenia treatment manic phase bipolar disorder adult . It also use clinically treatment psychotic disorder child , adolescent adult . This protocol help elucidate feasibility study treatment psychotic disorder ziprasidone adolescent 13-17 year help facilitate study treatment psychosis novel agent favorable side effect weight gain profile . The duration study 7 week . Depending level symptom severity patient manage either Schizophrenia Research Unit ( SRU ) ( GAS &lt; 35 , CGI-S &gt; 5 ) , Children 's Day Unit ( CDU ) NYSPI . The seven week would encompass 3 day period begin study include time screen review lab result . Over period one two week patient titrate 120 mg/day ( 80 mg patient 45kg ) , , necessary , cross taper another SGA work successfully . Subjects respond medication 1 week target dose discontinue study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>1 . Children meet DSMIV criterion follow psychotic disorder : schizophreniform disorder , schizoaffective disorder , psychosis NOS , major depressive disorder psychotic feature , bipolar disorder psychotic feature . 2 . Children IQ least 70 . 3 . Children good physical health . 4 . The parent/guardian child must willing attend study visit . 1 . Children currently receive effective treatment without detrimental side effect . 2 . Children allergic Geodon速 . 3 . Children previously fail respond adequate trial Geodon速 . 4 . Females pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>psychosis NOS</keyword>
	<keyword>MDD w/ psychotic feature</keyword>
	<keyword>bipolar disorder w. psychotic feature</keyword>
</DOC>